Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

BACKGROUND: Invasive lobular carcinoma (ILC) accounts for 10–15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable mechanism underlying enhanced human epidermal growth factor 2 (HER2) ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurozumi, Sasagu, Alsaleem, Mansour, Monteiro, Cíntia J., Bhardwaj, Kartikeya, Joosten, Stacey E. P., Fujii, Takaaki, Shirabe, Ken, Green, Andrew R., Ellis, Ian O., Rakha, Emad A., Mongan, Nigel P., Heery, David M., Zwart, Wilbert, Oesterreich, Steffi, Johnston, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422515/
https://www.ncbi.nlm.nih.gov/pubmed/32782013
http://dx.doi.org/10.1186/s13058-020-01324-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422515/
https://www.ncbi.nlm.nih.gov/pubmed/32782013
http://dx.doi.org/10.1186/s13058-020-01324-4

Ejemplares similares